InsidersTradesSigma
Total declarations
Company
▲ Purchases (44 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
44
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by LONDONER KENNETH L, Founder, Chairman & Chief Executive Officer. Director active across 1 company, notably BioSig Technologies, Inc.. Aggregated, 70 filings have been logged. Split: 44 buys · 0 sell. Total volume traded: €436k. History available since 26 May 2021. The latest transaction was filed on 30 November 2023 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations70 total
219,700 shares0Common StockSEC:0001493152-23-043614:0
10,000 shares@ US$1.241.7% of flowCommon StockSEC:0001185185-23-000633:0
Canonical exit: 11 Sept 2023 (T+90)
2,000 shares@ US$1.100.3% of flowCommon StockSEC:0001185185-23-000631:0
Canonical exit: 10 Sept 2023 (T+90)
1,000 shares@ US$1.560.2% of flowCommon StockSEC:0001185185-23-000625:0
Canonical exit: 29 Aug 2023 (T+90)
576,000 shares0Common StockSEC:0001185185-23-000462:0
7,006 shares@ US$0.840.9% of flowCommon StockSEC:0001185185-22-001087:0
Canonical exit: 7 Dec 2022 (T+90)
500 shares@ US$1.0990.1% of flowCommon StockSEC:0001185185-22-001075:0
Canonical exit: 6 Dec 2022 (T+90)
3,000 shares@ US$1.090.5% of flowCommon StockSEC:0001185185-22-001067:0
Canonical exit: 1 Dec 2022 (T+90)
17,240 shares@ US$1.08492.7% of flowCommon StockSEC:0001185185-22-001057:0
Canonical exit: 30 Nov 2022 (T+90)
1,000 shares@ US$1.080.2% of flowCommon StockSEC:0001185185-22-001031:0
Canonical exit: 27 Nov 2022 (T+90)
7,400 shares@ US$1.191.3% of flowCommon StockSEC:0001185185-22-001025:0
Canonical exit: 23 Nov 2022 (T+90)
5,000 shares@ US$1.050.8% of flowCommon StockSEC:0001185185-22-001004:0
Canonical exit: 21 Nov 2022 (T+90)
3,000 shares@ US$1.010.4% of flowCommon StockSEC:0001185185-22-000976:0
Canonical exit: 17 Nov 2022 (T+90)
500 shares@ US$0.880.1% of flowCommon StockSEC:0001185185-22-000970:0
Canonical exit: 15 Nov 2022 (T+90)
3,000 shares@ US$0.9220.4% of flowCommon StockSEC:0001185185-22-000961:0
Canonical exit: 14 Nov 2022 (T+90)
9,300 shares@ US$1.151.6% of flowCommon StockSEC:0001185185-22-000699:0
Canonical exit: 23 Aug 2022 (T+90)
8,744 shares@ US$1.0981.4% of flowCommon StockSEC:0001185185-22-000692:0
Canonical exit: 22 Aug 2022 (T+90)
3,650 shares@ US$1.130.6% of flowCommon StockSEC:0001185185-22-000688:0
Canonical exit: 18 Aug 2022 (T+90)
20,000 shares0Common StockSEC:0001185185-22-000002
20,000 shares0Common StockSEC:0001185185-22-000002:0
2,636 shares@ US$2.810.9% of flowCommon StockSEC:0001185185-21-001398
Canonical exit: 19 Dec 2021 (T+90)
2,636 shares@ US$2.811.0% of flowCommon StockSEC:0001185185-21-001398:0
Canonical exit: 19 Dec 2021 (T+90)
3,000 shares@ US$3.69671.5% of flowCommon StockSEC:0001185185-21-001243:0
Canonical exit: 26 Aug 2021 (T+90)
3,200 shares@ US$3.42691.4% of flowCommon StockSEC:0001185185-21-001239:0
Canonical exit: 24 Aug 2021 (T+90)
2,000 shares@ US$3.5650.9% of flowCommon StockSEC:0001185185-21-001249:0
Canonical exit: 5 Sept 2021 (T+90)
25 of 70 declarations
About LONDONER KENNETH L
Kenneth L. Londoner is best known as the founder, Chairman, and Chief Executive Officer of BioSig Technologies, Inc., a U.S.-listed medical technology company focused on cardiac signal visualization and arrhythmia analysis. His career has been closely tied to medtech innovation, company building, and the commercialization of technologies intended to improve the quality and interpretability of intracardiac signals. At BioSig, he helped shape the company’s strategic direction around the PURE EP™ platform, which is designed to provide greater clarity in arrhythmia identification and cardiac electrophysiology workflows. Across his broader career, Londoner has been active in leadership, investing, and business development roles in healthcare and medical devices. Corporate filings show that he also served as a director of MedClean Technologies, Inc., and that he was involved as a business partner and investor in InspireMD, another medical device company. These roles suggest a consistent focus on healthcare innovation, early-stage company development, and strategic growth opportunities in regulated industries. At BioSig, Londoner’s most visible contribution has been as a founder-led executive with responsibility for long-term vision, corporate positioning, and strategic execution. The company’s core mission has been to reduce noise and interference in cardiac recordings, helping physicians interpret signals more clearly during procedures such as cardiac ablations. BioSig has also highlighted initiatives involving artificial intelligence and software-enabled healthcare applications, indicating an effort to extend the company’s platform beyond hardware into broader digital health capabilities. Overall, Kenneth L. Londoner can be characterized as an entrepreneurial medtech executive with experience in company formation, governance, capital markets positioning, and product strategy. For SEO purposes, he is appropriately described as a founder and public-company leader in cardiovascular technology, with a career centered on medical device innovation, strategic growth, and clinical problem-solving.
